| | |
Page
|
| |||
| | | | 2 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 19 | | | |
| | | | 30 | | | |
| | | | 31 | | | |
| | | | 42 | | | |
| | | | 43 | | | |
| | | | 44 | | | |
| | | | 44 | | | |
| | | | 47 | | | |
| | | | 48 | | | |
| | | | 49 | | | |
| | | | 50 | | | |
| | | | 52 | | | |
| | | | 52 | | | |
| | | | 52 | | |
|
Proposal 1: Elect Directors
|
| | The three director nominees who receive the most votes (also known as a “plurality” of the votes cast) will be elected. You may vote either FOR all of the nominees, WITHHOLD your vote from all of the nominees or WITHHOLD your vote from any one or more of the nominees. Votes that are withheld will not be included in the vote tally for the election of the directors. Brokerage firms do not have authority to vote customers’ unvoted shares held by the firms in street name for the election of the directors. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote. | |
|
Proposal 2: Approve an Advisory Vote on the Compensation of Our Named Executive Officers
|
| | The affirmative vote of a majority of the votes cast affirmatively or negatively for this proposal is required to approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote customers’ unvoted shares held by the firms in street name on this proposal. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote. Although the advisory vote is non-binding, the Compensation Committee and our Board of Directors will review the voting results and take them into consideration when making future decisions regarding executive compensation. | |
|
Proposal 3: Approve an Advisory Vote on the Frequency of Holding an Advisory Vote on the Compensation of Our Named Executive Officers
|
| | The frequency of holding an advisory vote on the compensation of our named executive officers — every year, every two years or every three years — receiving a majority of the votes cast will be the frequency approved by our stockholders. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote customers’ unvoted shares held by the firms in street name on this proposal. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote. Although the advisory vote is non-binding, the Compensation Committee and our Board of Directors will review the voting results and take them into consideration when determining the frequency of holding an advisory vote on the compensation of our named executive officers for the next six years. | |
|
Proposal 4: Ratify Appointment of Independent Registered Public Accounting Firm
|
| | The affirmative vote of a majority of the votes cast affirmatively or negatively for this proposal is required to ratify the appointment of our independent registered public accounting firm. Abstentions will have no effect on the results of this vote. Brokerage firms have authority to vote customers’ unvoted shares held by the firms in street name on this proposal. If a broker does not exercise this authority, such broker non-votes will have no effect on the results of this vote. We are not required to obtain the approval of our stockholders to appoint our independent registered public accounting firm. However, if our stockholders do not ratify the appointment of Ernst & Young LLP as our independent | |
| | | | registered public accounting firm for 2022, the Audit Committee of our Board of Directors will reconsider its appointment. | |
| | |
Shares Beneficially
Owned |
| | |||||||||||
Name and Address of Beneficial Owner
|
| |
Number
|
| |
Percent
|
| | | | ||||||
Principal Stockholders | | | | | | | | | | | | | | | | |
Macquarie Group Limited, 50 Martin Place, Sydney, New South Wales, Australia (1)
|
| | | | 3,154,600 | | | | | | 8.1% | | | | | |
Gilder, Gagnon, Howe & Co. LLC, 475 10th Avenue, New York, NY 10018(2)
|
| | | | 2,835,999 | | | | | | 7.3% | | | | | |
Blackrock, Inc., 55 East 52nd Street, New York, NY 10055(3)
|
| | | | 2,456,075 | | | | | | 6.3 | | | | | |
Directors, Director Nominees and Named Executive Officers | | | | | | | | | | | | | | | | |
E. Kevin Hrusovsky(4)
|
| | | | 1,350,774 | | | | | | 3.4% | | | | | |
Keith L. Crandell(5)
|
| | | | 147,681 | | | | | | * | | | | | |
Martin D. Madaus, Ph.D.(6)
|
| | | | 212,341 | | | | | | * | | | | | |
Sarah E. Hlavinka(7)
|
| | | | 43,763 | | | | | | * | | | | | |
Paul M. Meister (8)
|
| | | | 69,681 | | | | | | * | | | | | |
Laurie J. Olson(9)
|
| | | | 7,655 | | | | | | * | | | | | |
David R. Walt, Ph.D.(10)
|
| | | | 1,310,244 | | | | | | 3.4% | | | | | |
Masoud Toloue, Ph.D.(11)
|
| | | | 16,691 | | | | | | * | | | | | |
Michael A. Doyle
|
| | | | — | | | | | | — | | | | | |
John Fry(12)
|
| | | | 73,874 | | | | | | * | | | | | |
Dawn R. Mattoon, Ph.D.(13)
|
| | | | 63,258 | | | | | | * | | | | | |
Shawn Stetson(14)
|
| | | | 7,705 | | | | | | * | | | | | |
Amol Chaubal(15)
|
| | | | ** | | | | | | ** | | | | | |
William Geist(16)
|
| | | | ** | | | | | | ** | | | | | |
All directors and current executive officers as a group (10 persons)(17)
|
| | | | 3,232,704 | | | | | | 8.2% | | | | | |
Name
|
| |
Age
|
| |
Position with the Company
|
|
E. Kevin Hrusovsky | | |
60
|
| | Executive Chairman of the Board of Directors | |
Masoud Toloue, Ph.D. | | |
42
|
| | President and Chief Executive Officer and Director | |
Keith L. Crandell(2)(3) | | |
62
|
| | Director | |
Sarah E. Hlavinka(1)(3) | | |
57
|
| | Director | |
Martin D. Madaus, Ph.D.(1)(3) | | |
62
|
| | Director | |
Paul M. Meister(1) | | |
69
|
| | Director | |
Laurie J. Olson(2) | | |
59
|
| | Director | |
David R. Walt, Ph.D.(2) | | |
69
|
| | Director | |
Name
|
| |
Age
|
| |
Position(s) with the Company
|
|
E. Kevin Hrusovsky | | |
60
|
| | Executive Chairman | |
Masoud Toloue, Ph.D. | | |
42
|
| | President and Chief Executive Officer | |
Michael A. Doyle | | |
66
|
| | Chief Financial Officer | |
John Fry | | |
60
|
| | General Counsel and Secretary | |
Name
|
| |
Title as of December 31, 2021
|
|
E. Kevin Hrusovsky | | | President and Chief Executive Officer | |
Masoud Toloue | | | President of Quanterix and Diagnostics | |
Michael Doyle | | | Chief Financial Officer and Treasurer | |
John Fry | | | General Counsel and Secretary | |
Dawn Mattoon | | | Senior Vice President, Diagnostics | |
|
What We Do:
|
| |
What We Don’t Do:
|
|
| Reward performance according to pre-established performance goals | | | Pay cash incentives if performance levels fall below pre-determined thresholds | |
| Provide a meaningful portion of the compensation of our Chief Executive Officer and Named Executive Officers through performance-based or at-risk compensation | | | Permit hedging or pledging of our stock | |
| Establish stock ownership guidelines for our executive officers | | | Enter into employment agreements that provide for automatic compensation increases or equity grants | |
| The Compensation Committee retains an independent compensation consultant | | | Provide single trigger change of control benefits | |
| Beginning in 2022, we plan to hold an annual advisory vote on executive compensation | | | Provide for excessive cash severance | |
| Cap payouts under our compensation plans to discourage inappropriate risk taking by our executives | | | Provide our executives with golden parachute tax gross-ups | |
| Provide for double-trigger change in control severance provisions | | | Maintain executive pension plans or other retirement programs that are not generally available to all employees | |
Element
|
| |
Award Vehicle
|
| |
Guaranteed
vs. At-Risk |
| |
Performance
vs. Time-Based |
|
Base Salary | | |
Cash
|
| |
Guaranteed
|
| |
Not applicable
|
|
Annual Cash Incentive Bonus | | |
Cash
|
| |
At-Risk
|
| |
Performance-Based
|
|
Long-Term Incentive Equity | | |
Restricted Stock Units (“RSUs”) and Stock Options
|
| |
At-Risk
|
| |
Time-Based
|
|
| Axonics Modulation Technologies, Inc. | | | Luminex Corporation | |
| CareDx, Inc. | | | Meridian Bioscience, Inc. | |
| Castle Biosciences, Inc. | | | Nanostring Technologies, Inc. | |
| Codexis, Inc. | | | Natera Inc. | |
| Cryoport Systems, Inc. | | | Pacific Biosystems of California, Inc. | |
| Fluidigm Corporation | | | Personalis, Inc. | |
| GenMark Diagnostics, Inc. | | | Twist Bioscience Corporation | |
| Heska Corporation | | | Veracyte, Inc. | |
Executive
|
| |
2020 Base Salary
|
| |
2021 Base Salary
|
| |
% Change
|
| |||||||||
E. Kevin Hrusovsky
|
| | | $ | 552,000 | | | | | $ | 600,000 | | | | | | 9% | | |
Masoud Toloue(1)
|
| | | | — | | | | | $ | 525,000 | | | | | | — | | |
Michael Doyle(2)
|
| | | | — | | | | | $ | 415,000 | | | | | | — | | |
John Fry
|
| | | $ | 354,000 | | | | | $ | 364,000 | | | | | | 3% | | |
Dawn Mattoon
|
| | | $ | 330,000 | | | | | $ | 345,000 | | | | | | 5% | | |
Amol Chaubal(3)
|
| | | $ | 371,000 | | | | | $ | 415,000 | | | | | | 12% | | |
Shawn Stetson(4)
|
| | | $ | 198,000 | | | | | $ | 222,390 | | | | | | 12% | | |
William Geist(5)
|
| | | $ | 400,000 | | | | | $ | 400,000 | | | | | | 0% | | |
Executive
|
| |
2020 Target
Award (% of Base Salary Earned) |
| |
2021 Target
Award (% of Base Salary Earned) |
| ||||||
E. Kevin Hrusovsky
|
| | | | 100% | | | | | | 100% | | |
Masoud Toloue(1)
|
| | | | — | | | | | | 100% | | |
Michael Doyle(2)
|
| | | | — | | | | | | 50% | | |
John Fry
|
| | | | 50% | | | | | | 50% | | |
Dawn Mattoon
|
| | | | 45% | | | | | | 50% | | |
Amol Chaubal(3)
|
| | | | 45% | | | | | | 55% | | |
Shawn Stetson(4)
|
| | | | 20% | | | | | | 20% | | |
William Geist(5)
|
| | | | 50% | | | | | | 50% | | |
| | |
Weight
|
| |
Threshold
(0.5x) |
| |
Target
(1.0x) |
| |
Maximum
(1.5x) |
| |
Actual
|
| |
Measure
|
| |
Weighted Payout
|
|
Revenue(1) | | |
60%
|
| |
$91.8 million
|
| |
$110.2 million
|
| |
$128.6 million
|
| |
$105.3 million
|
| |
0.87
|
| |
0.522
|
|
Gross Margin(1)
|
| |
20%
|
| |
52%
|
| |
56%
|
| |
60%
|
| |
55.4%
|
| |
0.92
|
| |
0.185
|
|
Strategic Objectives
|
| |
20%
|
| |
2 of 4
achieved |
| |
4 of 4
achieved |
| |
All 4 achieved
and 3 exceed expectations |
| |
3 of 4
achieved, 1 exceeded expectations |
| |
0.75
|
| |
0.150
|
|
Total
|
| |
100%
|
| | | | | | | | | | | | | | | | |
0.86
|
|
| | | | | | | | | | | | | | | | | |
As Adjusted
|
| |
1.0
|
|
Executive
|
| |
Base Salary
Earned in 2021 ($)(1) |
| |
Target Award
(% of Base Salary) |
| |
Corporate
Performance Factor |
| |
Individual
Performance Factor |
| |
Payment ($)
|
| |||||||||||||||
Kevin Hrusovsky
|
| | | | 596,594 | | | | | | 100% | | | | | | 1.0x | | | | | | 1.0x | | | | | | 596,594 | | |
Masoud Toloue(2)
|
| | | | 298,846 | | | | | | 100% | | | | | | 1.0x | | | | | | 1.0x | | | | | | 298,846 | | |
Michael Doyle(3)
|
| | | | 199,519 | | | | | | 50% | | | | | | 1.0x | | | | | | 1.0x | | | | | | 99,760 | | |
John Fry
|
| | | | 364,160 | | | | | | 50% | | | | | | 1.0x | | | | | | 0.95x | | | | | | 172,976 | | |
Dawn Mattoon
|
| | | | 344,491 | | | | | | 50% | | | | | | 1.0x | | | | | | 1.1x | | | | | | 189,470 | | |
Shawn Stetson(4)
|
| | | | 222,226 | | | | | | 20% | | | | | | 1.0x | | | | | | 1.05x | | | | | | 46,667 | | |
Executive
|
| |
2020
Award Value ($) |
| |
2021 Award
Value ($) |
| |
Number of
Stock Options |
| |
Number of
RSUs |
| ||||||||||||
Kevin Hrusovsky
|
| | | $ | 2,100,000 | | | | | $ | 3,000,000 | | | | | | 42,925 | | | | | | 18,397 | | |
Masoud Toloue(1)
|
| | | | — | | | | | | — | | | | | | | | | | | | | | |
Michael Doyle(2)
|
| | | | — | | | | | | — | | | | | | | | | | | | | | |
John Fry
|
| | | $ | 600,000 | | | | | $ | 600,000 | | | | | | 8,585 | | | | | | 3,679 | | |
Dawn Mattoon
|
| | | $ | 600,000 | | | | | $ | 600,000 | | | | | | 8,585 | | | | | | 3,679 | | |
Amol Chaubal(3)
|
| | | $ | 500,000 | | | | | $ | 944,000 | | | | | | 13,507 | | | | | | 5,789 | | |
Shawn Stetson(4)
|
| | | $ | 55,000 | | | | | $ | 75,000 | | | | | | 831 | | | | | | 554 | | |
William Geist (5)
|
| | | | — | | | | | $ | 800,000 | | | | | | 11,447 | | | | | | 4,906 | | |
| | | |
Members of the Compensation Committee:
Keith L. Crandell (Chairman) Laurie Olson David R. Walt, Ph.D. |
|
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($)(1) |
| |
Stock Awards
($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total ($)
|
| |||||||||||||||||||||
E. Kevin Hrusovsky
Executive Chairman and Former Chief Executive Officer |
| | | | 2021 | | | | | | 592,628 | | | | | | — | | | | | | 3,008,520 | | | | | | 596,594 | | | | | | 10,452 | | | | | | 4,208,194 | | |
| | | 2020 | | | | | | 554,286 | | | | | | 769,449 | | | | | | 2,185,995 | | | | | | — | | | | | | 10,667 | | | | | | 3,520,397 | | | ||
| | | 2019 | | | | | | 531,969 | | | | | | 770,024 | | | | | | 2,319,301 | | | | | | — | | | | | | 9,702 | | | | | | 3,630,996 | | | ||
Michael A. Doyle(5)
Chief Financial Officer |
| | | | 2021 | | | | | | 183,558 | | | | | | — | | | | | | 730,786 | | | | | | 99,760 | | | | | | — | | | | | | 1,014,104 | | |
Shawn Stetson(6)
Former Interim Chief Financial Officer |
| | | | 2021 | | | | | | 221,075 | | | | | | — | | | | | | 224,904 | | | | | | 46,667 | | | | | | 6,632 | | | | | | 499,278 | | |
| | | 2020 | | | | | | 205,029 | | | | | | 60,911 | | | | | | 56,771 | | | | | | — | | | | | | 6,151 | | | | | | 328,862 | | | ||
| | | 2019 | | | | | | 95,250 | | | | | | 34,480 | | | | | | 112,375 | | | | | | — | | | | | | 2,700 | | | | | | 244,805 | | | ||
Amol Chaubal(7)
Former Chief Financial Officer |
| | | | 2021 | | | | | | 156,038 | | | | | | — | | | | | | 946,711 | | | | | | — | | | | | | 4,107 | | | | | | 1,106,856 | | |
| | | 2020 | | | | | | 371,188 | | | | | | 330,992 | | | | | | 520,521 | | | | | | — | | | | | | 4,219 | | | | | | 1,226,920 | | | ||
| | | | | 2019 | | | | | | 253,077 | | | | | | 145,772 | | | | | | 940,255 | | | | | | — | | | | | | 4,321 | | | | | | 1,343,425 | | |
Masoud Toloue, Ph.D.(8)
President and Chief Executive Officer; Former President of Quanterix and Diagnostics |
| | | | 2021 | | | | | | 278,654 | | | | | | — | | | | | | 3,061,463 | | | | | | 298,846 | | | | | | — | | | | | | 3,638,963 | | |
John Fry
General Counsel and Secretary |
| | | | 2021 | | | | | | 362,400 | | | | | | — | | | | | | 601,736 | | | | | | 172,976 | | | | | | 8,829 | | | | | | 1,145,941 | | |
| | | 2020 | | | | | | 354,594 | | | | | | 239,904 | | | | | | 624,637 | | | | | | — | | | | | | 5,938 | | | | | | 1,225,073 | | | ||
| | | | | 2019 | | | | | | 192,231 | | | | | | 115,339 | | | | | | 1,372,337 | | | | | | — | | | | | | 5,375 | | | | | | 1,685,282 | | |
Dawn R. Mattoon, Ph.D.
Senior Vice President, Clinical Diagnostics |
| | | | 2021 | | | | | | 342,631 | | | | | | — | | | | | | 601,736 | | | | | | 189,470 | | | | | | 8,700 | | | | | | 1,142,537 | | |
| | | 2020 | | | | | | 330,917 | | | | | | 239,940 | | | | | | 624,598 | | | | | | — | | | | | | 9,299 | | | | | | 1,204,754 | | | ||
| | | 2019 | | | | | | 314,462 | | | | | | 190,523 | | | | | | 371,699 | | | | | | — | | | | | | 8,929 | | | | | | 885,613 | | | ||
William Geist(9)
Former Chief Operating Officer |
| | | | 2021 | | | | | | 361,539 | | | | | | — | | | | | | 802,329 | | | | | | — | | | | | | 756,370 | | | | | | 1,920,238 | | |
| | | 2020 | | | | | | 52,308 | | | | | | 530,000 | | | | | | 1,900,936 | | | | | | — | | | | | | 1,338 | | | | | | 2,484,582 | | |
Name
(a) |
| |
Grant
Date (b) |
| |
Estimated Future Payouts Under
Non-Equity Incentive Plan Awards(1) |
| |
All Other Stock
Awards: Number of Shares of Stock or Units (#)(2) (i) |
| |
All Other Option
Awards: Number of Securities Underlying Options (#)(3) (j) |
| |
Exercise or Base
Price of Option Awards ($/Sh) (k) |
| |
Grant Date Fair
Value of Stock and Option Awards ($)(4) (l) |
| ||||||||||||||||||||||||||||||
|
Threshold
($) (c) |
| |
Target
($) (d) |
| |
Maximum ($)
(e) |
| |||||||||||||||||||||||||||||||||||||||||
E. Kevin Hrusovsky
|
| | | | — | | | | | | 300,000 | | | | | | 600,000 | | | | | | 900,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/8/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | 18,397 | | | | | | — | | | | | | — | | | | | | 1,431,103 | | | ||
| | | | | 2/8/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 42,925 | | | | | | 77.79 | | | | | | 1,577,418 | | |
Michael A. Doyle
|
| | | | — | | | | | | 49,800 | | | | | | 99,760 | | | | | | 164,604 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 7/12/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,530 | | | | | | — | | | | | | — | | | | | | 329,975 | | | ||
| | | | | 7/12/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 12,904 | | | | | | 59.67 | | | | | | 400,811 | | |
Shawn Stetson
|
| | | | — | | | | | | 22,239 | | | | | | 44,478 | | | | | | 73,389 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/10/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | 554 | | | | | | — | | | | | | — | | | | | | 44,032 | | | ||
| | | | | 2/10/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 831 | | | | | | 79.48 | | | | | | 31,186 | | |
| | | | | 5/11/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,423 | | | | | | — | | | | | | — | | | | | | 70,012 | | |
| | | | | 5/11/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,321 | | | | | | 49.20 | | | | | | 79,674 | | |
Amol Chaubal
|
| | | | — | | | | | | 114,125 | | | | | | 228,250 | | | | | | 376,613 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2/8/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,789 | | | | | | — | | | | | | — | | | | | | 450,326 | | |
| | | | | 2/8/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 13,507 | | | | | | 77.79 | | | | | | 496,385 | | |
Masoud Toloue, Ph.D.
|
| | | | — | | | | | | 149,423 | | | | | | 298,846 | | | | | | 493,096 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/9/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,703 | | | | | | — | | | | | | — | | | | | | 3,061,463 | | | ||
John Fry
|
| | | | — | | | | | | 91,000 | | | | | | 182,000 | | | | | | 300,300 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2/8/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,679 | | | | | | — | | | | | | — | | | | | | 286,189 | | |
| | | | | 2/8/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 8,585 | | | | | | 77.79 | | | | | | 315,546 | | |
Dawn R. Mattoon, Ph.D.
|
| | | | — | | | | | | 86,250 | | | | | | 172,500 | | | | | | 284,625 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/8/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,679 | | | | | | — | | | | | | — | | | | | | 286,189 | | | ||
| | | | | 2/8/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 8,585 | | | | | | 77.79 | | | | | | 315,546 | | |
William Geist
|
| | | | — | | | | | | 86,250 | | | | | | 172,500 | | | | | | 284,625 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/8/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | 4,906 | | | | | | — | | | | | | — | | | | | | 381,638 | | | ||
| | | | | 2/8/21 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 11,447 | | | | | | 77.79 | | | | | | 420,691 | | |
| | |
Option Awards(1)
|
| |
Stock Awards(1)
|
| ||||||||||||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options Exercisable (#) |
| |
Number of
Securities Underlying Unexercised Options Unexercisable (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of Shares
or Units of Stock That Have Not Vested (#) |
| |
Market Value of
Shares or Units of Stock That Have Not Vested ($)(2) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Number of Shares or Units or Other Rights That Have Not Vested ($) |
| ||||||||||||||||||||||||
E. Kevin Hrusovsky
Executive Chairman and Former Chief Executive Officer |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 39,815(3) | | | | | | 1,688,156 | | |
| | | 311,138(4) | | | | | | — | | | | | $ | 8.16 | | | | | | 3/31/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 76,610(5) | | | | | | 31,567(5) | | | | | $ | 22.69 | | | | | | 3/12/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,936(5) | | | | | | 336,486 | | | | | | — | | | | | | — | | | ||
| | | 28,323(6) | | | | | | 11,677(6) | | | | | $ | 30.45 | | | | | | 8/17/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,985(6) | | | | | | 126,564 | | | | | | — | | | | | | — | | | ||
| | | 43,593(7) | | | | | | 47,399(7) | | | | | $ | 27.76 | | | | | | 2/18/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,316(7) | | | | | | 861,398 | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | 42,925(8) | | | | | $ | 77.79 | | | | | | 2/8/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 18,397(8) | | | | | | 780,033 | | | | | | — | | | | | | — | | | ||
Michael A. Doyle
Chief Financial Officer |
| | | | — | | | | | | 12,904(9) | | | | | $ | 59.67 | | | | | | 7/12/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,530(9) | | | | | | 234,472 | | | | | | — | | | | | | — | | |
| | |
Option Awards(1)
|
| |
Stock Awards(1)
|
| ||||||||||||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options Exercisable (#) |
| |
Number of
Securities Underlying Unexercised Options Unexercisable (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of Shares
or Units of Stock That Have Not Vested (#) |
| |
Market Value of
Shares or Units of Stock That Have Not Vested ($)(2) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Number of Shares or Units or Other Rights That Have Not Vested ($) |
| ||||||||||||||||||||||||
Shawn Stetson
Former Interim Chief Financial Officer |
| | | | 3,226(10) | | | | | | 1,774(10) | | | | | $ | 31.91 | | | | | | 7/25/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 567(10) | | | | | | 24,041 | | | | | | — | | | | | | — | | | ||
| | | 881(7) | | | | | | 972(7) | | | | | $ | 27.76 | | | | | | 2/18/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 652(7) | | | | | | 27,645 | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | 831(11) | | | | | $ | 79.48 | | | | | | 2/10/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 554(11) | | | | | | 23,490 | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | 3,321(12) | | | | | $ | 49.20 | | | | | | 5/11/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,423(12) | | | | | | 60,335 | | | | | | — | | | | | | — | | | ||
Amol Chaubal
Former Chief Financial Officer |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Masoud Toloue, Ph.D.
President and Chief Executive Officer |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,073(13) | | | | | | 2,123,095 | | | | | | — | | | | | | — | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
John Fry
General Counsel and Secretary |
| | | | 33,048(14) | | | | | | 18,129(14) | | | | | $ | 33.48 | | | | | | 6/14/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,985(14) | | | | | | 338,564 | | | | | | — | | | | | | — | | | ||
| | | 12,451(7) | | | | | | 13,549(7) | | | | | $ | 27.76 | | | | | | 2/18/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,806(7) | | | | | | 246,174 | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | 8,585(8) | | | | | $ | 77.79 | | | | | | 2/8/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,679(8) | | | | | | 155,990 | | | | | | — | | | | | | — | | | ||
Dawn R. Mattoon, Ph.D.
Senior Vice President, Clinical Diagnostics |
| | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
| | | 21,225(15) | | | | | | 845(15) | | | | | $ | 22.12 | | | | | | 2/23/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 8,361(16) | | | | | | 2,196(16) | | | | | $ | 19.12 | | | | | | 5/10/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 640(16) | | | | | | 27,136 | | | | | | | | | | | | | | | ||
| | | 14,110(17) | | | | | | 7,194(17) | | | | | $ | 22.69 | | | | | | 3/12/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,121(17) | | | | | | 89,930 | | | | | | — | | | | | | — | | | ||
| | | 10,421(7) | | | | | | 13,549(7) | | | | | $ | 27.76 | | | | | | 2/18/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,806(7) | | | | | | 246,174 | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | 8,585(8) | | | | | $ | 77.79 | | | | | | 2/8/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,679(8) | | | | | | 155,990 | | | | | | — | | | | | | — | | | ||
William Geist
Former Chief Operating Officer |
| | | | 5,008(18) | | | | | | — | | | | | $ | 77.79 | | | | | | 2/12/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
Option Awards
|
| |
Stock Awards(1)
|
| ||||||||||||||||||
Name
|
| |
Number of
Shares Acquired on Exercise (#) |
| |
Value
Realized on Exercise ($)(2) |
| |
Number of
Shares Acquired on Vesting (#) |
| |
Value Realized
on Vesting ($)(3) |
| ||||||||||||
E. Kevin Hrusovsky
|
| | | | — | | | | | | — | | | | | | 104,157 | | | | | | 6,015,704 | | |
Michael A. Doyle
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Shawn Stetson
|
| | | | — | | | | | | — | | | | | | 955 | | | | | | 62,142 | | |
Amol Chaubal
|
| | | | 39,197 | | | | | | 1,191,805 | | | | | | 4,420 | | | | | | 339,676 | | |
Masoud Toloue, Ph.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
John Fry
|
| | | | — | | | | | | — | | | | | | 10,953 | | | | | | 688,778 | | |
Dawn R. Mattoon, Ph.D.
|
| | | | 38,920 | | | | | | 1,456,867 | | | | | | 11,553 | | | | | | 721,639 | | |
William Geist
|
| | | | — | | | | | | — | | | | | | 28,836 | | | | | | 1,329,916 | | |
Name
|
| |
Base Salary
($) |
| |
Lump
Sum Payments ($) |
| |
Continuation of
Group Health Plan Benefits ($) |
| |
Non-Equity
Incentive Plan Payments ($) |
| |
Equity
Incentive Plan Payments ($)(1) |
| |
Total ($)
|
| ||||||||||||||||||
E. Kevin Hrusovsky
|
| | | | 300,000 | | | | | | — | | | | | | 7,406 | | | | | | 596,594 | | | | | | — | | | | | | 904,000 | | |
Michael A. Doyle
|
| | | | 415,000 | | | | | | 210,000 | | | | | | 14,813 | | | | | | 99,760 | | | | | | 87,853 | | | | | | 827,426 | | |
Shawn Stetson(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 46,667 | | | | | | — | | | | | | 46,667 | | |
Masoud Touloue
|
| | | | 525,000 | | | | | | 525,000 | | | | | | 22,797 | | | | | | 298,846 | | | | | | 1,120,250 | | | | | | 2,491,893 | | |
John Fry
|
| | | | 182,000 | | | | | | — | | | | | | 11,398 | | | | | | 172,976 | | | | | | 472,182 | | | | | | 838,556 | | |
Dawn Mattoon
|
| | | | — | | | | | | — | | | | | | — | | | | | | 189,470 | | | | | | — | | | | | | 189,470 | | |
Name
|
| |
Base Salary
($) |
| |
Lump
Sum Payments ($) |
| |
Continuation of
Group Health Plan Benefits ($) |
| |
Non-Equity
Incentive Plan Payments ($) |
| |
Equity
Incentive Plan Payments ($)(1) |
| |
Total ($)
|
| ||||||||||||||||||
E. Kevin Hrusovsky
|
| | | | 600,000 | | | | | | — | | | | | | 14,813 | | | | | | 596,594 | | | | | | — | | | | | | 1,211,407 | | |
Michael A. Doyle
|
| | | | 415,000 | | | | | | 210,000 | | | | | | 14,813 | | | | | | 99,760 | | | | | | 234,472 | | | | | | 974,045 | | |
Shawn Stetson(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 46,667 | | | | | | — | | | | | | 46,667 | | |
Masoud Touloue
|
| | | | 525,000 | | | | | | 525,000 | | | | | | 22,797 | | | | | | 298,846 | | | | | | 2,123,095 | | | | | | 3,494,738 | | |
John Fry
|
| | | | 364,000 | | | | | | — | | | | | | 22,797 | | | | | | 172,976 | | | | | | 472,182 | | | | | | 1,031,955 | | |
Dawn Mattoon(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 189,470 | | | | | | — | | | | | | 189,470 | | |
Name
|
| |
Fees Earned
or Paid in Cash ($)(1) |
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(2) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| |||||||||||||||
Keith L. Crandell
|
| | | | 51,952 | | | | | | 100,130 | | | | | | 154,292 | | | | | | — | | | | | | 306,374 | | |
Marijn Dekkers, Ph.D.(3)
|
| | | | 41,000 | | | | | | 100,130 | | | | | | 154,292 | | | | | | — | | | | | | 295,422 | | |
Sarah E. Hlavinka
|
| | | | 47,445 | | | | | | 100,130 | | | | | | 154,292 | | | | | | — | | | | | | 301,867 | | |
Martin D. Madaus, Ph.D.
|
| | | | 72,375 | | | | | | 100,130 | | | | | | 154,292 | | | | | | — | | | | | | 326,797 | | |
Paul M. Meister
|
| | | | 54,951 | | | | | | 100,130 | | | | | | 154,292 | | | | | | — | | | | | | 309,373 | | |
Laurie J. Olson
|
| | | | 17,306 | | | | | | 300,321 | | | | | | 497,608 | | | | | | | | | | | | 815,235 | | |
David R. Walt, Ph.D.
|
| | | | 41,000 | | | | | | 100,130 | | | | | | 154,292 | | | | | | — | | | | | | 295,422 | | |
Name
|
| |
Aggregate
Number of Shares Subject to Stock Options |
| |||
Keith L. Crandell
|
| | | | 31,600 | | |
Marijn Dekkers, Ph.D.(3)
|
| | | | 7,900 | | |
Sarah E. Hlavinka
|
| | | | 31,600 | | |
Martin D. Madaus, Ph.D.
|
| | | | 31,600 | | |
Paul M. Meister
|
| | | | 54,935 | | |
Laurie J. Olson
|
| | | | 15,800 | | |
David R. Walt, Ph.D.
|
| | | | 31,600 | | |
|
Stock Ownership Guideline
|
| | Non-Employee Director | | | 5x annual base cash retainer | |
| | | | CEO | | | 6x annual base salary | |
| | | | Executive Officers Other than CEO | | | 3x annual base salary | |
|
Attainment Period
|
| |
Five years from the later of
•
Appointment/election to applicable position
•
October 9, 2019
|
| |||
|
Stock Owned for Purposes of Ownership Guidelines
|
| |
•
Stock acquired on the open market;
•
Stock acquired through the exercise of options;
•
Restricted stock, RSUs and stock options, whether vested or unvested; and
•
Stock acquired through Company benefit plans.
|
| |||
|
Holding Requirement
|
| | 50% of “net of tax” vested shares must be held until the ownership guideline is met. | | |||
|
Administration
|
| | The Stock Ownership Guidelines are administered by the Compensation Committee, which evaluates compliance on an annual basis. Non-compliance arising from special circumstances, such as fluctuations in the Company’s stock price, changes in a participant’s compensation, and the personal financial situation of a participant, are reviewed by the Compensation Committee. | |
| | |
(a)
|
| |
(b)
|
| |
(c)
|
| |||||||||
Plan category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights |
| |
Weighted-
average exercise price of outstanding options, warrants and rights |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| |||||||||
Equity compensation plans approved by security holders(1)
|
| | | | 2,204,813 | | | | | $ | 16.57 | | | | | | 2,571,667(2) | | |
Equity compensation plans not approved by security holders
|
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 2,204,813 | | | | | $ | 16.57 | | | | | | 2,571,667(2) | | |
| | |
2020
|
| |
2021
|
| ||||||
Audit fees:(1)
|
| | | $ | 1,436,414 | | | | | $ | 2,118,350 | | |
Audit-related fees:(2)
|
| | | | — | | | | | | — | | |
Tax fees:(3)
|
| | | | 56,350 | | | | | | 49,350 | | |
Total
|
| | | $ | 1,492,764 | | | | | $ | 2,167,700 | | |